Ensysce Biosciences (ENSCW) Non-Current Deffered Revenue (2017 - 2021)

Ensysce Biosciences (ENSCW) has 5 years of Non-Current Deffered Revenue data on file, last reported at $2.0 million in Q1 2021.

• Non-Current Deffered Revenue for Q1 2021 came in at $2.0 million, down 71.43% year-over-year; the trailing twelve-month figure through Mar 2021 was $2.0 million (down 71.43% YoY), and the FY2020 annual result was $6.8 million, down 3.57% from the prior year.
• Non-Current Deffered Revenue declined to $2.0 million in Q1 2021 per ENSCW's latest filing, from $6.8 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $7.0 million in Q4 2017 and troughed at $2.0 million in Q1 2021.
• A 5-year average of $6.6 million and a median of $7.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2018 and 2021: Non-Current Deffered Revenue changed 0.0% in 2018, then tumbled 71.43% in 2021.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $7.0 million in 2017, then changed by 0.0% to $7.0 million in 2018, then changed by 0.0% to $7.0 million in 2019, then slipped by 3.57% to $6.8 million in 2020, then slumped by 70.37% to $2.0 million in 2021.
• Business Quant data shows ENSCW's Non-Current Deffered Revenue at $2.0 million in Q1 2021, $6.8 million in Q4 2020, and $7.0 million in Q3 2020.